This free online CME/NCPD activity on first-line and second-line treatment for advanced renal cell carcinoma is presented by Bradley McGregor, MD, and Robert Motzer, MD. It is also available as a podcast. Start the activity now!

In this virtual tumor board, Sara M. Tolaney, MD, MPH, Ira J. Bleiweiss, MD, and Mikel Ross, MSN, RN, AGPCNP-BC, OCN®, CBCN, assess predictive and prognostic markers for MBC, evaluate current and emerging data on therapeutic approaches for HER2-positive, hormone receptor-positive/HER2-negative, and triple-negative MBC, and apply strategies to manage adverse events for MBC. Start now!

This CME virtual tumor board, presented by Loretta J. Nastoupil, MD, Reem Karmali, MD, MS, and Francisco Vega, MD, PhD, evaluates emerging efficacy and safety data on novel therapeutic approaches, discusses the implications of POD24 status in therapeutic decision making for patients, and applies strategies to optimize treatment experiences and outcomes for patients with relapsed/refractory FL. Start now!

In this free online CME activity, Tanios S. Bekaii-Saab, MD, uses a case-based approach to discuss prognostic factors that can tailor treatment to individual patients, novel therapies, and optimizing treatment experiences for patients with newly diagnosed and relapsed/refractory metastatic colorectal cancer.

On this second bonus episode of Oncology Data Advisor, Bradley McGregor, MD, and Robert Motzer, MD, discuss first-line and second-line treatments for advanced renal cell carcinoma. Also available as a video. Listen now and earn CME/NCPD!